Clinical Scorecard: Comparative Analysis of Blood Pressure Outcomes in Obstructive Sleep Apnea: Mandibular Advancement Devices Versus CPAP in Randomized Controlled Trials - A Systematic Review and Meta-Analysis

At a Glance

Key Highlights

• Mandibular advancement devices (MAD) show comparable cardiovascular benefits to CPAP.
• MAD achieved a greater reduction in daytime systolic blood pressure compared to CPAP.
• CPAP is superior in reducing the apnea-hypopnea index (AHI).
• MAD demonstrated significantly longer nightly adherence than CPAP.
• MAD may serve as a viable alternative for OSA patients intolerant to CPAP.

Guideline-Based Recommendations

Diagnosis

• Screen hypertensive patients for OSA.
• Diagnosis via polysomnography or home sleep monitoring.

Management

• CPAP is the first-line treatment for OSA.
• MAD is recommended for patients intolerant to CPAP.

Monitoring & Follow-up

• Track blood pressure pre- and post-treatment.
• Monitor adherence to treatment using objective data.

Risks

• Suboptimal adherence to CPAP can limit its effectiveness.
• Potential cardiovascular risks associated with untreated OSA.

Patient & Prescribing Data

Patients with obstructive sleep apnea, particularly those with cardiovascular risk.

MAD may provide cardiovascular benefits and improved adherence for some patients.

Clinical Best Practices

• Utilize objective adherence tracking for treatment evaluation.
• Consider MAD for patients with mild-to-moderate OSA or those intolerant to CPAP.

Related Resources & Content

• Systematic Review Registration